Sort by
Medicine and Dentistry
Lung
100%
Community-Acquired Pneumonia
64%
Endomicroscopy
35%
Ex Vivo
34%
Non Small Cell Lung Cancer
32%
Molecular Imaging
29%
Lung Cancer
25%
Cancer Associated Fibroblast
25%
COVID-19
24%
Pulmonary Embolism
18%
Lung Nodule
18%
Systematic Review
18%
T Cell
17%
Fibroblast
16%
Lifespan
15%
Artificial Respiration
15%
Biopsy Technique
14%
Intensive Care Unit
14%
Matrix Metalloproteinase
13%
Antibiotic Therapy
13%
Meta-Analysis
13%
Odds Ratio
12%
Lung Cancer Screening
12%
Raman Spectrometry
12%
Fluorescence-Lifetime Imaging Microscopy
12%
Optical Imaging
12%
Tumor
12%
Autofluorescence
12%
In Vitro
12%
Imaging Agent
12%
Pneumonia Severity Index
11%
Fluorescence Microscopy
11%
Glass Fiber
11%
Hypertensive Factor
11%
Infection
10%
Acute Pulmonary Embolism
9%
Bacterium Detection
9%
Neutrophil
9%
Leukocyte Activation
9%
Health Care Cost
8%
Low Drug Dose
8%
Imaging Technique
8%
Arm
8%
Immunotherapy
7%
Cytotoxic T-Cell
7%
Confocal Laser Scanning Microscopy
7%
Polypeptide Antibiotic Agent
7%
Cohort Effect
7%
Decision Making
7%
Secretion (Process)
7%
Immunology and Microbiology
Cancer Associated Fibroblast
37%
T Cell
29%
Antimicrobial Peptides
26%
Bacterium Detection
18%
Fluorescence Microscopy
18%
In Vitro
16%
Peptides
14%
Infection
14%
Autofluorescence
13%
CXCL13
13%
Neutrophil
12%
COVID-19
12%
Immunopathology
12%
Molecular Imaging
11%
Fibroblast
10%
Infectious Agent
10%
Pseudomonas aeruginosa
9%
Bacterial Load
7%
Immunotherapy
7%
Cytotoxic T-Cell
7%
Secretion (Process)
7%
Aspergillus fumigatus
7%
Proteomics
6%
Macrophage
6%
Transforming Growth Factor Beta
6%
Negative Feedback
6%
T Lymphocyte Subpopulation
6%
Tumor Immunology
6%
Adoptive Immunity
6%
Support Vector Machine
6%
Hepatocyte Growth Factor
6%
Human Tissue
6%
C-Reactive Protein
6%
Tumor Necrosis Factor
6%
Microorganism Detection
6%
Gram-Negative Bacteria
6%
Cohort Effect
6%
Leukocyte Activation
6%
Immune Response
5%
Stroma
5%
Protein Secondary Structure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Community Acquired Pneumonia
49%
Pharmacokinetics
14%
Pharmacodynamics
14%
Polypeptide Antibiotic Agent
12%
Non Small Cell Lung Cancer
12%
Lower Respiratory Tract Infection
12%
Randomized Controlled Trial
12%
Infection
10%
Chronic Obstructive Lung Disease
10%
Hypertensive Factor
9%
Coronavirinae
9%
Diseases
7%
Antibiotic Therapy
6%
Cystic Fibrosis
6%
Pneumothorax
6%
Pleura Effusion
6%
Antiinfective Agent
6%
Lung Enzyme
6%
Clarithromycin
6%
Galectin 3
6%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
6%
Lung Nodule
6%
Clinical Study
6%
Acute Heart Infarction
6%
Cardiovascular Risk
6%
Amino Acid
6%
Clinical Trial
6%
Optical Imaging
6%
Acute Kidney Failure
6%
Nafamstat
6%
Nafamstat Mesilate
6%
Clostridium Difficile Infection
6%
Ventilator Associated Pneumonia
6%
Matrix Metalloproteinase
6%
Prospective Cohort Study
6%
Direct DNA Damage
6%
Add on Therapy
6%
Inflammation
5%
Biological Marker
5%
